The acquisition provided over €500 million investment, which comes after the company announced a €1 billion investment across its sites in Carlow and Dunboyne, Co Meath, just last year.
MSD and WuXi will now begin an official handover process which aims to be completed in the first half of 2025.
The newly acquired Dundalk site is a 15,520-square-metre, three-story vaccine manufacturing facility featuring drug substance manufacturing, drug product manufacturing, and quality control labs for the supply of vaccine products for the global market, currently employing approximately 200 professionals on site.
Samantha Humphreys, Managing Director of MSD Ireland Human Health, said: “Our company’s continued ambition to expand MSD’s Irish footprint is a testament to the unique ecosystem around us, and in particular speaks to the passion, commitment and talent of our existing 3,000-strong workforce and what they have been able to accomplish for our global network – from MSD Ireland to the world. I am very proud to be part of this exciting new chapter as we continue to expand, adding new capabilities and challenging ourselves to look at the health requirements of the future.”
